Free tool
FAERS Monitor: Cotempla Xr-Odt
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 205489 or its brand name (Cotempla Xr-Odt, Methylphenidate). Reports on generic versions are filed under their own applications.
Reports
15,349
Serious
10,239
67% of reports
Hospitalization
3,634
Death reported
1,114
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,503
- off label use921
- fatigue782
- nausea731
- anxiety727
- toxicity to various agents688
- headache680
- depression578
- insomnia511
- somnolence503
- condition aggravated497
- dizziness488
- vomiting462
- product substitution issue434
- drug abuse415
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 10 |
| 2005 | 26 |
| 2006 | 12 |
| 2007 | 6 |
| 2008 | 5 |
| 2009 | 19 |
| 2010 | 165 |
| 2011 | 233 |
| 2012 | 302 |
| 2013 | 425 |
| 2014 | 423 |
| 2015 | 749 |
| 2016 | 1,521 |
| 2017 | 1,106 |
| 2018 | 1,060 |
| 2019 | 1,082 |
| 2020 | 928 |
| 2021 | 870 |
| 2022 | 1,094 |
| 2023 | 1,347 |
| 2024 | 1,384 |
| 2025 | 1,422 |
| 2026 | 1,160 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,038,810 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product substitution issueSignal | 434 | 10.4 | 9.5 | 3,660 |
| drug abuseSignal | 415 | 6.9 | 6.2 | 2,070 |
| toxicity to various agentsSignal | 688 | 5.6 | 5.2 | 2,612 |
| anxietySignal | 727 | 3.5 | 3.3 | 1,315 |
| depressionSignal | 578 | 3.5 | 3.2 | 1,031 |
| somnolenceSignal | 503 | 3.4 | 3.1 | 869 |
| insomniaSignal | 511 | 2.6 | 2.4 | 521 |
| condition aggravatedSignal | 497 | 2.2 | 2.1 | 345 |
| drug ineffective | 1,503 | 1.6 | 1.5 | 325 |
| headache | 680 | 1.5 | 1.4 | 111 |
| off label use | 921 | 1.4 | 1.4 | 129 |
| fatigue | 782 | 1.4 | 1.3 | 83 |
| vomiting | 462 | 1.3 | 1.2 | 42 |
| dizziness | 488 | 1.3 | 1.2 | 43 |
| nausea | 731 | 1.3 | 1.2 | 42 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.